Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 4/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 8/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257985 | 0.81 | NISCH (0.51) | PDCD1LG2CD274NISCH | |
| SCHEMBL12362313 | 0.79 | NISCH (0.50) | PDCD1LG2CD274NISCH | |
| SCHEMBL81737 | 0.76 | NISCH (0.40) | PDCD1LG2CD274NISCH | |
| SCHEMBL82845 | 0.74 | KDM4E (0.47) | PDCD1LG2CD274NISCHMAOB | |
| SCHEMBL29618250 | 0.72 | NISCH (0.42) | PDCD1LG2CD274NISCHADRA1DADRA1A | |
| SCHEMBL1655501 | 0.72 | NISCH (0.42) | PDCD1LG2CD274NISCHADRA1DADRA1A | |
| SCHEMBL4383292 | 0.72 | NISCH (0.70) | PDCD1LG2CD274NISCH | |
| SCHEMBL31743071 | 0.72 | NISCH (0.54) | PDCD1LG2CD274NISCH | |
| SCHEMBL2258437 | 0.72 | NISCH (0.58) | PDCD1LG2CD274NISCHADRA2AADRA2B | |
| SCHEMBL8194659 | 0.71 | NISCH (0.58) | PDCD1LG2CD274NISCHADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859572-B2 | Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20110190281-A1 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190281-A1 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3CB | PDCD1LG2 3347/4885CD274 4402/4885NISCH 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.